Related Experiment Video

Updated: Aug 1, 2025

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.2K

Association Between Serum Irisin Levels and ST-Segment Elevation Myocardial Infarction

Derya Ozturk1, Adem Melekoglu1, Ertugrul Altinbilek1

  • 1Sisli Hamidiye Etfal Education and Research Hospital, Department of Emergency, İstanbul, Turkey.

International Journal of General Medicine
|April 24, 2023
PubMed

Insights

Lower serum irisin levels are highly predictive of ST-elevation myocardial infarction (STEMI). This study suggests irisin is a promising biomarker for acute myocardial infarction (AMI) severity, correlating with cardiac troponin-I levels.

Area of Science:

  • Cardiology
  • Biochemistry
  • Biomarkers

Background:

  • ST-elevation myocardial infarction (STEMI) is a critical cardiovascular condition with significant morbidity and mortality risks.
  • Irisin, an adipomyokine, is linked to various health conditions, with elevated levels post-STEMI associated with adverse cardiovascular events.

Purpose of the Study:

  • To investigate the association between serum irisin levels and acute myocardial infarction (AMI).
  • To determine if irisin can serve as a biomarker for AMI severity in STEMI patients.
  • To explore correlations between serum irisin and cardiac troponin-I (cTi) levels.

Main Methods:

  • The study included 90 participants: 46 controls and 44 STEMI patients.
  • Evaluated demographic data, medical history (diabetes, hypertension), ECG findings, blood biochemistry, cardiac biomarkers (cTi), and serum irisin levels.

Main Results:

  • STEMI patients exhibited significantly lower heart rate and higher ST-elevation and QTc intervals compared to controls (p < 0.05).
  • Serum irisin levels were significantly lower in STEMI patients (p < 0.001).
  • Decreased irisin levels correlated with increased cTi and QTc (p < 0.05), with 93% sensitivity and 78% specificity.

Conclusions:

  • Reduced irisin levels are highly predictive of STEMI.
  • Serum irisin levels in STEMI patients are associated with cTi and QTc intervals.
  • Irisin shows promise as a biomarker for assessing acute myocardial infarction severity.
Abstract

Keywords:
QT intervalbiomarkercardiovascular diseasesirisinmyocardial infarctiontroponin-I

More Related Videos

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

16.8K
Histological Quantification of Chronic Myocardial Infarct in Rats09:45

Histological Quantification of Chronic Myocardial Infarct in Rats

Published on: December 11, 2016

14.7K

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
211
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
36
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
15
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
25
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
14
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
129